QP Declaration vs. GMP Certificate
Recommendation
10/11 February 2026
Heidelberg, Germany
Medicinal Products/Drugs meet Medical Devices
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
The Co-ordination Group for Mutual Recognition and Decentralised Procedures - Human (CMDh), a group of the Heads of Medicines Agencies (HMA), has updated its Questions & Answer Document on Applications for Marketing Authorisation (CMDh/268/2012).
The latest amendment is dealing with the question whether a member state can invalidate a procedure because a GMP Certificate was not provided for an API for which the QP declaration was provided.
The answer is: "No. A satisfactory QP Declaration is always necessary and is normally sufficient to confirm that the manufacture of active pharmaceutical ingredients (APIs) comply with Good Manufacturing Practice (GMP), as required by Article 8 Paragraph 3 (ha) of Directive 2001/83/EC."
Related GMP News
04.02.2026When Training Falls Short: FDA Findings on GMP Training Deficiencies in 2025
27.01.2026New Ph. Eur. Publication Schedule
21.01.2026EU Pharma Package: EMA with single Point of Information
14.01.2026European QP Association Developments September through December 2025
14.01.2026Could a change of ownership be relevant to GMP?
07.01.2026Is QP Certification required when Products do not enter EU Territory?